The impact of coding germline variants on contralateral breast cancer risk and survival
Anna Morra(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Patricia Harrington(Roswell Park Comprehensive Cancer Center), Hiltrud Brauch(German Cancer Research Center), Brennan Decker(Boston Foundation), Peter A. Fasching(Universitätsklinikum Erlangen), Graham G. Giles(The University of Melbourne), Melissa H. Cessna(Intermountain Healthcare), Jose E. Castelao(Servicio Gallego de Salud), Jenny Chang‐Claude(Universität Hamburg), Manuela Gago-Domínguez(University of Southern California), Thilo Dörk(Hannover Re (Germany)), Jonine D. Figueroa, Melanie Gündert(German Cancer Research Center), Heiko Becher(Universität Hamburg), Päivi Auvinen(University of Eastern Finland), Joe Dennis(University of Cambridge), Jürgen Geisler(Oslo University Hospital), Kristine Kleivi Sahlberg(University of Oslo), Pascal Guénel(Inserm), Mikael Eriksson(Herlev Hospital), Alison M. Dunning(University of Cambridge), Kamila Czene(Karolinska Institutet), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Jamie Allen(University of Cambridge), Arif B. Ekici(University Medical Center Groningen), Thomas U. Ahearn(Harvard University), Nasim Mavaddat(MRC Epidemiology Unit), Irene L. Andrulis(University of Toronto), Sabine Behrens(German Cancer Research Center), Per Hall(Karolinska Institutet), Inger Torhild Gram(St. Elizabeth's Hospital), Carl Blomqvist(University of Helsinki), Willemina R.R. Geurts-Giele(Erasmus MC), Ute Hamann(German Cancer Research Center), Nicola J. Camp(University of Utah), Karina Standahl Olsen(UiT The Arctic University of Norway), Eric Hahnen(University Hospital Cologne), Stig E. Bojesen(University of Copenhagen), Montserrat García‐Closas(Institute of Cancer Research), Leila Dorling(Cancer Research UK Cambridge Center), D. Gareth Evans(Manchester Academic Health Science Centre), Taru Muranen(Karolinska Institutet), Sara Carvalho(University of Cambridge), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Henrik Flyger(Herlev Hospital), Manjeet K. Bolla(University of Cambridge), Bjørn Naume(Norwegian Cancer Society), Grethe I.G. Alnæs(Oslo University Hospital), Olav Engebråten(University of Oslo)
Cited by 28
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k